Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1332270rdf:typepubmed:Citationlld:pubmed
pubmed-article:1332270lifeskim:mentionsumls-concept:C0042776lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C0014644lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C0006072lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C1333227lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C0599566lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C1998793lld:lifeskim
pubmed-article:1332270lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:1332270pubmed:issue11lld:pubmed
pubmed-article:1332270pubmed:dateCreated1992-12-1lld:pubmed
pubmed-article:1332270pubmed:abstractTextOur initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases.lld:pubmed
pubmed-article:1332270pubmed:languageenglld:pubmed
pubmed-article:1332270pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:citationSubsetIMlld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1332270pubmed:statusMEDLINElld:pubmed
pubmed-article:1332270pubmed:issn0264-410Xlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:ArrandJ RJRlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:QualtiereL...lld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:MackettMMlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:MadejMMlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:MorganA JAJlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:ConwayM JMJlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:WallaceLLlld:pubmed
pubmed-article:1332270pubmed:authorpubmed-author:SweetJJlld:pubmed
pubmed-article:1332270pubmed:issnTypePrintlld:pubmed
pubmed-article:1332270pubmed:volume10lld:pubmed
pubmed-article:1332270pubmed:ownerNLMlld:pubmed
pubmed-article:1332270pubmed:authorsCompleteYlld:pubmed
pubmed-article:1332270pubmed:pagination777-82lld:pubmed
pubmed-article:1332270pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:meshHeadingpubmed-meshheading:1332270-...lld:pubmed
pubmed-article:1332270pubmed:year1992lld:pubmed
pubmed-article:1332270pubmed:articleTitlePurification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.lld:pubmed
pubmed-article:1332270pubmed:affiliationDepartment of Molecular Biology, Paterson Institute for Cancer Research, Manchester, UK.lld:pubmed
pubmed-article:1332270pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1332270pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1332270lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1332270lld:pubmed